Deep Dutta MD, ADA 2019 – Diabetes and Weight Loss
We were delighted to meet new Editorial Board member Dr Deep Dutta at the ADA conference to discuss the role of diet and exercise in diabetes management and the importance of weight loss.
Filmed at the American Diabetes Association (ADA) annual meeting 2019, San Francisco, USA.
1. Why is it so important for type 2 diabetes patients with obesity to lose weight? (0:05)
2. What is the role of diet and exercise in weight loss? (1:05)
3. What is the current status of weight loss medications which are approved for use? (1:40)
4. What is the role of anti-diabetes medications for weight loss in diabetes? (2:36)
5. What is the new concept of Multi-Drug Therapy for optimizing weight loss strategies in “diabesity”? (3:18)
Deep Dutta has no conflicts of interest to declare in relation to this video
touchENDO.com is an independent information resource supporting physicians, clinicians and leading industry professionals in continuously developing their knowledge, effectiveness and productivity, via free-to-access content in multimedia formats.
Share this Video
Related Videos In Obesity
Domenica Rubino, EASD 2022: The role of semaglutide in the treatment paradigm for prediabetes
Semaglutide has clinically beneficial effects on glucose metabolism and glycaemic status in patients with obesity and prediabetes. In this touchENDOCRINOLOGY interview, Dr Domenica Rubino (Washington Center for Weight Management and Research, Arlington, VA , USA) discusses her thoughts on the role of semaglutide in the treatment paradigm for prediabetes. The abstract entitled: ‘Semaglutide 2.4 mg […]
Domenica Rubino, EASD 2022: Semaglutide 2.4 mg vs liraglutide 3.0 mg on glucose metabolism – STEP 8 post-hoc analysis
The aim of the STEP 8 trial (NCT04074161) was to compare the effect and safety of semaglutide 2.4 mg once weekly compared to liraglutide 3.0 mg once daily on weight management in people with obesity. In this touchENDOCRINOLOGY interview, Dr Domenica Rubino (Washington Center for Weight Management and Research, Arlington, VA , USA) discusses the […]
Uberto Pagotto, ESPE 2022: GLP-1 agonists and other emerging treatments of obesity
Glucagon-like peptide-1 agonists are a class of medications utilized in the treatment of type 2 diabetes and obesity. In this touchENDOCRINOLOGY interview, Prof. Uberto Pagotto (University of Bologna, Bologna, Italy) discusses the impact of glucagon-like peptide 1 agonists on obesity, what other emerging treatments in obesity appear promising. The future direction in obesity research is […]
Journal articles and more to your inbox
Get the latest clinical insights from touchENDOCRINOLOGYSign me up!